FDA Class I Medical Device Regulations and Compliance

Jenn Dixon

and

October 2, 2024

Class I Medical Device Regulations and Compliance

The intricate world of medical device compliance and regulations can be daunting, particularly for manufacturers of Class I medical devices. Often perceived as less complex due to Class I devices being the “lowest tier” of FDA’s medical device classification list, Class I devices still require meticulous attention to regulatory details to ensure market entry and sustained success. In this blog, we'll delve into the essential compliance and regulatory framework that governs Class I medical devices. From understanding the specific FDA requirements to the nuances of labeling, 21 CFR Part 820 compliance, and post-market surveillance, our goal is to provide you with a comprehensive guide that simplifies this complex landscape.

What is a Class I Medical Device?

Named “Class I devices” by the Federal Drug Administration (FDA), Class I medical devices have the lowest risk to users, and are subject to less regulatory scrutiny compared to Class II and Class III devices. The FDA states, “Class I devices are not intended to be:

For use in supporting or sustaining life;
Of importance in preventing impairment to human life; and may not
Present a potential unreasonable risk of illness or injury.”

However, this does not imply a straightforward path to market. Manufacturers must navigate a series of regulatory requirements, ensuring their products meet all applicable standards for safety and effectiveness.

Class I Medical Device Exemptions and Requirements

Most Class I devices are exempt from premarket notification requirements, commonly known as the 510(k) or De Novo submission. However, manufacturers are still required to adhere to other regulatory obligations, including specific 21 CFR Part 820 compliance, labeling requirements, and medical device reporting (MDR). A majority of Class I medical devices are not subjected to the same stringent requirements of 21 CFR Part 820, which are generally required for Class II and Class III devices. It is crucial for manufacturers to verify their device's exemption status since some Class I devices may not qualify for this exemption based on their specific function or risk profile. See the FDA's website for an up to date list.

General Controls for Class I Devices

Class I medical devices must follow a list of General Controls outlined by the FDA. General Controls apply to all three classes of medical devices; however, they are usually the only level of controls that apply to Class I devices. The list of these General Controls include:

Adulteration
Misbranding
Device registration and listing
Premarket notification
Banned devices
Notification and repair, replacement, and refund
Records and reports
Restricted devices
Good Manufacturing Practices

Class I Medical Device Examples:

Class I devices are common medical instruments that the average person would be able to recognize and identify. Class I device examples include:

Latex gloves
Surgical masks
Tongue depressors
Stethoscopes
Bandages
Irrigating dental syringes
Non-electric wheelchair
Thermometers (basic digital and mercury)
Handheld surgical instruments
Bedpans
Electric toothbrush
Oxygen mask
Reusable surgical scalpel
Hospital beds

Examples of Class I Medical Devices

Class I Medical Device 21 CFR Part 820 Compliance

Class I devices are generally exempt from premarket notification, as well as the FDA’s Quality System Regulation (QSR), outlined in 21 CFR Part 820, as part of the current good manufacturing practice (CGMP). However, there are Class I devices that still need to follow aspects of 21 CFR Part 820, specifically Subpart C - Design Controls. The Class I devices that need to follow the 21 CFR Part 820 Subpart C - Design Controls are any devices that are automated with computer software, as well as tracheobronchial suction catheters, non-powdered surgical gloves, protective restraints, manual radionuclide applicator systems, and radionuclide teletherapy sources - as listed below in paragraph (a) (2) of 21 CFR Part 820.

This regulation mandates that manufacturers shall establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met. Key components of 21 CFR Part 820 - Subpart C include:

Design and Development Planning: Manufacturers must create comprehensive plans outlining design and development activities, assigning clear responsibilities. These plans should detail interactions with various groups providing critical input throughout the design process. As projects progress, these plans require regular reviews, updates, and approvals to ensure they remain aligned with evolving design and development objectives.
Design Input: Manufacturers are required to formulate and uphold procedures that capture design requirements specific to a device’s intended function, user needs, and patient requirements. These procedures must also address any incomplete, ambiguous, or conflicting design requirements effectively. All design inputs need to be documented, with their approval recorded by assigned personnel, noting approval dates and signatures.
Design Output: Procedures for defining and documenting design outputs must be maintained, ensuring these outputs are described in a manner that facilitates an effective evaluation against the design inputs. Essential design outputs, critical for the device’s functionality, must be clearly identified. The completion of design output includes thorough documentation, review, and formal approval before any release.
Design Review: It is imperative that manufacturers establish protocols for periodic and structured design reviews conducted at critical stages of the device's development. These reviews should involve cross-functional teams and an independent reviewer who is not directly involved in the design phase under review, to ensure an unbiased process. Details of the design reviews, including outcomes and participants, should be methodically documented within the design history file (DHF).
Design Verification: Manufacturers must ensure the existence of procedures that verify the device design aligns with and meets all design input specifications. Verification should be comprehensive, with all findings and methodologies carefully recorded in the DHF, including details of the personnel involved.
Design Validation: Validation procedures are crucial to confirm that the device meets user requirements and intended uses under actual or simulated operating conditions. This includes the validation of software and risk analysis where necessary. The validation process should be applied to initial production units or their equivalents, with all results and details documented in the DHF.
Design Transfer: Effective procedures must be in place to ensure the accurate conversion of device designs into production specifications, maintaining the integrity of the design through to manufacturing.
Design Changes: There must be a structured approach to managing design changes, which includes the identification, documentation, validation (or verification), review, and approval before implementation. This ensures that modifications are thoroughly evaluated and integrated without compromising the design integrity.
Design History File: Each device type must have a corresponding DHF that aggregates or references all records necessary to demonstrate that the design was developed in accordance with the established plans and regulatory requirements. This file serves as a comprehensive archive of the design process, safeguarding the traceability and accountability of design activities.

Labeling Requirements for Class I Medical Devices

The labeling requirements for Class I medical devices, as specified by the FDA, are outlined primarily in 21 CFR Part 801, as well as in this FDA document. These requirements include several key elements that manufacturers must adhere to ensure compliance:

Name and Place of Business: The label must include the name and place of business (address, city, state, zip code) of the manufacturer, packer, or distributor. If the address is available in the local telephone directory, it can be omitted from the label. If the listed firm is not the manufacturer, the relationship (e.g., "Manufactured for..." or "Distributed by...") must be stated clearly.
Intended Use: The label should clearly state the intended uses of the device. If a device is intended for different uses than originally specified by the manufacturer, adequate labeling reflecting these new uses must be provided.
Adequate Directions for Use: This includes clear and concise instructions enabling a layperson to use the device safely and effectively. The directions should cover aspects such as the quantity of dose, frequency and duration of administration, method of application, and any necessary preparations for use.
False or Misleading Statements: Labels must not contain any false or misleading statements concerning other products (devices, drugs, foods, or cosmetics).
Prominence of Statements: Required information must be prominently displayed on the label and should be legible under normal conditions of purchase and use.
Language Requirements: All required information must be in English unless the product is distributed solely in a U.S. territory where another language is predominant, in which case that language may be used.
Unique Device Identifier (UDI): Most medical devices, including Class I, must bear a UDI on their labels unless an exception applies. This helps in tracking and identifying devices throughout their distribution and use.

Post-Market Surveillance and Reporting

Manufacturers of Class I devices are subject to post-market surveillance requirements, including the mandatory reporting of any device-related adverse events or malfunctions that could lead to death or serious injury. This is part of the FDA’s Medical Device Reporting (MDR) regulation. Compliance with MDR requirements involves setting up an effective system for monitoring and evaluating device performance in the real world, and reporting adverse events within specified timeframes.

How Ketryx can Help with Class I Medical Device Compliance and Regulations

Ketryx supports Class I medical device software manufacturers in many ways. First, Ketryx streamlines the documentation process, allowing medical device software manufacturers to automatically create FDA-compliant documentation when/if it is needed for the FDA. Ketryx’s built-in traceability and documentation processes enable compliance with lifecycle requirements, meeting ISO 62304 and 21 CFR Part 820 standards. Ketryx also includes capabilities for risk management, quality assurance and post-market surveillance to allow manufacturers to focus on the product and have peace of mind that they are staying in compliance with FDA regulations.

Interview transcript

Jenn Dixon

Client Operations Manager

Ketryx

Jenn Dixon leads quality and regulatory client engagements at Ketryx, where she provides coaching and support for clients wishing to adopt the best Software Medical Device practices. Jenn brings extensive expertise in quality assurance, regulatory affairs, and project management from previous roles in the MedTech industry with a proven ability to develop and apply best practices that optimize both teams and processes.

Prior to Ketryx, Jenn was Director of QA/RA at Omniscient Neurotechnology, overseeing global regulatory submissions, maintaining ISO 13485 compliance, and managing cross-functional teams in areas such as post-market surveillance and Good Machine Learning Practices (GMLP). Jenn also served as a Design Assurance Specialist and Technical Project Manager, where she excelled in risk management, audit readiness, and leading agile development teams to deliver innovative solutions.

Jenn began her career at Synaptive Medical, supporting ISO 13485 compliance transitions and leading UDI implementation. She holds a Bachelor’s degree in Engineering from the University of Toronto.